KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Accumulated Expenses (2016 - 2025)

Astrazeneca has reported Accumulated Expenses over the past 11 years, most recently at $7.3 billion for Q4 2025.

  • Quarterly results put Accumulated Expenses at $7.3 billion for Q4 2025, up 12.3% from a year ago — trailing twelve months through Dec 2025 was $7.3 billion (up 12.3% YoY), and the annual figure for FY2025 was $7.3 billion, up 12.3%.
  • Accumulated Expenses for Q4 2025 was $7.3 billion at Astrazeneca, up from $6.5 billion in the prior quarter.
  • Over the last five years, Accumulated Expenses for AZN hit a ceiling of $7.3 billion in Q4 2025 and a floor of $5.6 billion in Q4 2022.
  • Median Accumulated Expenses over the past 5 years was $6.1 billion (2023), compared with a mean of $6.2 billion.
  • Biggest five-year swings in Accumulated Expenses: surged 44.66% in 2021 and later decreased 1.73% in 2022.
  • Astrazeneca's Accumulated Expenses stood at $5.6 billion in 2021, then decreased by 1.73% to $5.6 billion in 2022, then grew by 10.11% to $6.1 billion in 2023, then rose by 5.74% to $6.5 billion in 2024, then rose by 12.3% to $7.3 billion in 2025.
  • The last three reported values for Accumulated Expenses were $7.3 billion (Q4 2025), $6.5 billion (Q4 2024), and $6.1 billion (Q4 2023) per Business Quant data.